

Media Release

Zug, 31 March 2014

Skyepharma announces £112 million capital increase and launches tender offer for outstanding bonds

Skyepharma plc (LSE: SKP), a public company in the portfolio of HBM Healthcare Investments, today announced a capital increase of £112 million through the issue of 58.7 million new shares at a price of £1.91 each. At the same time, the company is launching a tender offer for its £83.2 million (at face value) in outstanding bonds, at a price of 114.85 percent of the face amount.

HBM Healthcare Investments holds £49.97 million in face value of the bonds and 11.5 million shares of Skyepharma at a market value of £23.2 million, representing 24.9% ownership interest in the company.

HBM Healthcare Investments intends to participate in the capital increase by taking up its open offer entitlement of 14.1 million shares at a cost of £26.9 million. On completion of the transactions, HBM Healthcare Investments will receive proceeds from the tender offer for the bonds of £57.4 million. On the basis of an IRR to Skyepharma of 7.25 percent in relation to the tender offer for the bonds the book value of HBM Healthcare Investment's bond position as at 31 March 2014 will increase by £10.9 million. As a result, the net asset value (NAV) of each HBM share will increase by CHF 1.90.

The execution of the capital increase and the tender offer for the bonds are conditional upon resolutions of the shareholders and the bondholders of Skyepharma and are interconditional so that both transactions must be approved for them both to proceed. The General Meeting and the Bondholder Meeting will take place at the end of April 2014.

For further information, please contact Dr. Andreas Wicki on +41 41 768 11 08, or at andreas.wicki@hbmhealthcare.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 15 approved products in the areas of inhalation, oral, topical and injectable drug delivery, as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, please visit www.skyepharma.com.

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com